美國家庭壽險 (AFL) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, everyone, and welcome to the Aflac Incorporated fourth quarter 2025 earnings conference call. (Operator Instructions) Please also note today's event is being recorded.

    各位早安,歡迎參加 Aflac Incorporated 2025 年第四季財報電話會議。(接線員指示) 也請注意,今天的活動將會錄音。

  • I would now like to turn the floor over to David Young, Vice President of Capital Markets. Please go ahead.

    現在我想把時間交給資本市場副總裁 David Young。請開始。

  • David Young - Vice President - Capital Markets

    David Young - Vice President - Capital Markets

  • Good morning, and welcome. Thank you for joining us for Aflac Incorporated's fourth quarter 2025 earnings call. This morning, Dan Amos, Chairman, CEO of Aflac Incorporated, will provide an overview of our results and operations in Japan and the United States. Then Max Broden, Senior Executive Vice President and CFO of Aflac Incorporated, will provide more detail on our financial results for the quarter, current capital and liquidity. These topics are also addressed in the materials we posted with our earnings release, financial supplement and quarterly CFO update on our investors.aflac.com.

    各位早安,歡迎各位。感謝各位參加 Aflac Incorporated 2025 年第四季財報電話會議。今天上午,Aflac Incorporated 董事長兼執行長 Dan Amos 將概述我們在日本與美國的業績與營運情況。接著,Aflac Incorporated 資深執行副總裁兼財務長 Max Broden 將進一步說明本季財務結果、目前資本與流動性狀況。這些主題也已在我們隨財報新聞稿一併發布的資料中說明,包括財務補充資料與季度 CFO 更新,皆已張貼於 investors.aflac.com。

  • For Q&A today, we are joined by Virgil Miller, President of Aflac Incorporated and Aflac US; Charles Lake, Chairman and Representative Director, President of Aflac International; Masatoshi Koide, President and Representative Director, Aflac Life Insurance Japan; and Brad Dyslin, Global Chief Investment Officer, President of Aflac Global Investments.

    今天的問答環節,我們邀請到:Aflac Incorporated 與 Aflac US 總裁 Virgil Miller;Aflac International 董事長兼代表董事、總裁 Charles Lake;Aflac 人壽保險日本公司總裁兼代表董事 Masatoshi Koide;以及全球投資長、Aflac Global Investments 總裁 Brad Dyslin。

  • Before we begin, some statements in this teleconference are forward-looking within the meaning of federal securities laws. Although we believe these statements are reasonable, we can give no assurance that they will prove to be accurate because they are prospective in nature. Actual results could differ materially from those we discuss today. We encourage you to look at our annual report on Form 10-K for some of the various risk factors that could materially impact our results.

    在開始之前,本次電話會議中的部分陳述依據聯邦證券法屬於前瞻性陳述。雖然我們認為這些陳述是合理的,但由於其具有前瞻性,我們無法保證其將被證實為準確。實際結果可能與我們今天討論的內容存在重大差異。我們建議各位查閱我們的 Form 10-K 年度報告,其中列示了可能對我們業績造成重大影響的各項風險因素。

  • As I mentioned earlier, the earnings release with reconciliations of certain non-US GAAP measures and related earnings materials are available on investors.aflac.com. I'll now hand the call over to Dan. Dan?

    如我先前提到,包含特定非美國 GAAP 指標調節表的財報新聞稿,以及相關財報資料,皆可於 investors.aflac.com 取得。現在我把電話交給 Dan。Dan?

  • Daniel Amos - Chairman of the Board, Chief Executive Officer

    Daniel Amos - Chairman of the Board, Chief Executive Officer

  • Thank you, David, and good morning, everyone. We're glad you joined us. Aflac Incorporated reported fourth quarter net earnings per diluted share of $2.64, and adjusted earnings per diluted share of $1.57. For the year, Aflac Incorporated reported net earnings per diluted share of $6.82, and adjusted earnings per diluted share of $7.49. Max will expand upon these strong results for the quarter in a moment.

    謝謝你,David,各位早安。很高興各位加入我們。Aflac Incorporated 公布 2025 年第四季稀釋後每股淨利為 2.64 美元,調整後稀釋後每股盈餘為 1.57 美元。全年而言,Aflac Incorporated 稀釋後每股淨利為 6.82 美元,調整後稀釋後每股盈餘為 7.49 美元。Max 稍後將進一步說明本季這些強勁的成果。

  • But before he does, I'd like to comment on our operations. Beginning with Japan, I am very pleased with Aflac Japan sales increase of 15.7% for the fourth quarter and 16% for 2025. These strong sales results were driven largely by the remarkable 35.6% sales increase mainly due to Miraito, our latest cancer insurance product launched in March. While still early, we are also excited about the positive reception of our newest medical product, Anshin Palette, has received since its late December introduction.

    在他開始之前,我想先談談我們的營運。先從日本開始,我對 Aflac Japan 第四季銷售成長 15.7%,以及 2025 年全年成長 16% 感到非常滿意。這些強勁的銷售表現,主要來自銷售大幅成長 35.6%,其主因是我們於 3 月推出的最新癌症保險產品 Miraito。雖然仍在初期階段,我們也對最新醫療產品 Anshin Palette 自 12 月下旬推出以來獲得的正面回響感到振奮。

  • As part of our ongoing strategy, we also continue to emphasize and promote the importance of third sector protection, to new and younger customers with our innovative first sector product, Tsumitasu, which was repriced in September. While premium persistency reflected lapses tied to the launch of Miraito, it still remains strong at 93.1% for the year.

    作為我們持續策略的一部分,我們也持續強調並推廣第三領域保障的重要性,並透過我們創新的第一領域產品 Tsumitasu(已於 9 月重新訂價)來吸引新客戶與年輕客群。雖然保費續保率反映出與 Miraito 上市相關的解約情況,但全年仍維持在 93.1% 的強勁水準。

  • Our success with so many policyholders who realize the value of Aflac's products and keep them as a testament to Aflac's reputation, our strategy and our customers' recognition of the value of our products. By maintaining this level of persistency while adding new premium through sales, we look to offset the impact of reinsurance and policies reaching paid-up status in the future, maintaining strong persistency continues to be vital to the future of Aflac Japan.

    我們能在眾多保戶身上取得成功,這些保戶體認到 Aflac 產品的價值並持續持有,正是 Aflac 聲譽、我們策略,以及客戶對產品價值認可的明證。在維持此續保率水準、並透過銷售增加新保費的同時,我們期望在未來抵銷再保以及保單達到繳清狀態所帶來的影響;持續維持強勁的續保率,對 Aflac Japan 的未來仍至關重要。

  • For the year, we also saw an increase in sales through each distribution channel. Being where the customer wants to buy insurance has always been an important competitive strength of our growth strategy in Japan. Our broadened networks of distribution channels, including agencies, alliance partners and banks are dedicated to continually optimizing opportunities to help provide financial protection to Japanese consumers.

    全年來看,我們也看到各個通路的銷售皆有所成長。在日本,「在客戶想要購買保險的地方提供服務」一直是我們成長策略的重要競爭優勢。我們擴大的通路網絡,包括代理店、聯盟合作夥伴與銀行,致力於持續優化各項機會,以協助為日本消費者提供財務保障。

  • We will continue to work hard to support each channel as we evolve to meet customers' changing needs. Overall, I believe we have put in place the right people and the strategy to meet our customers' financial protection needs through their different stages of life.

    我們將持續努力支持各通路,並在演進過程中滿足客戶不斷變化的需求。整體而言,我相信我們已配置合適的人才與策略,能在客戶人生不同階段滿足其財務保障需求。

  • Turning to Aflac US. We generated nearly $1.6 billion in new sales in 2025, over one-third of which came from the fourth quarter. More importantly, we maintained strong premium persistency of 79.2% and increased net earned premiums by 2.9% for 2025. We continue to focus on driving our profitable growth by exercising a strong underwriting discipline and maintaining strong premium persistency. We believe this will continue to drive net earned premium growth.

    接著談 Aflac US。2025 年我們創造了接近 16 億美元的新契約銷售,其中超過三分之一來自第四季。更重要的是,我們維持了 79.2% 的強勁保費續保率,並使 2025 年淨已賺保費成長 2.9%。我們持續透過嚴謹的核保紀律與維持強勁的保費續保率,專注推動獲利性成長。我們相信這將持續帶動淨已賺保費的成長。

  • At the same time, Aflac US has continued its prudent approach to expense management and maintaining a strong pretax margin, as Max will expand upon shortly. In both Japan and the United States, consumers continue to face financial hardships due to increasing out-of-pocket medical expenses. That is exactly where we come in as partners to be there when our policyholders need us most.

    同時,Aflac US 也持續採取審慎的費用管理方式,並維持強勁的稅前利潤率,Max 稍後將進一步說明。在日本與美國,消費者仍因自付醫療費用上升而面臨財務壓力。這正是我們作為夥伴發揮作用之處——在保戶最需要我們的時候陪伴在側。

  • As the pioneer of cancer insurance and the leader in the industry, our management teams, employees and sales networks approach every day as a chance to help our policyholders, fill the gap during challenging times, providing not just financial protection, but also compassion and care. At the same time, we generate strong capital and cash flows on an ongoing basis while maintaining our commitment to prudent liquidity and capital management.

    作為癌症保險的先驅與產業領導者,我們的管理團隊、員工與銷售網絡每天都把握機會協助保戶,在艱難時刻填補缺口,提供的不僅是財務保障,也包含同理與關懷。同時,我們在持續維持審慎的流動性與資本管理承諾下,仍能穩定創造強勁的資本與現金流。

  • We continue to be pleased with our investments, producing solid net investment income. As an insurance company, our primary responsibility is to fulfill the promises we make to our policyholders while being responsive to the needs of our shareholders. Our financial strength is the foundation that backs up our promise to our policyholders, balanced with the financial flexibility and tactical capital deployment.

    我們對投資表現仍感到滿意,帶來穩健的淨投資收益。作為保險公司,我們的首要責任是履行對保戶的承諾,同時回應股東的需求。我們的財務實力是支撐對保戶承諾的基礎,並在此基礎上兼顧財務彈性與戰術性的資本配置。

  • I am very pleased with the company's financial strength, which supports our capital deployment including the Board's decision to increase the first quarter of 2026 dividend by 5.2%. In 2025, Aflac Incorporated deployed a record $3.5 billion to repurchase 33 million shares of our stock and paid dividends of $1.2 billion.

    我對公司的財務實力感到非常滿意,這也支持我們的資本配置,包括董事會決議將 2026 年第一季股利提高 5.2%。2025 年,Aflac Incorporated 以創紀錄的 35 億美元回購 3,300 萬股公司股票,並支付 12 億美元股利。

  • We treasure our 43 consecutive years of dividend increases and remain committed to extending this record. Combining share repurchase and dividends, we delivered nearly $4.8 billion back to the shareholders in 2025. In doing so, we have maintained our position among companies with the highest return on capital and the lowest cost of capital in the industry.

    我們珍視連續 43 年提高股利的紀錄,並將持續致力於延續這項紀錄。合計股票回購與股利,我們在 2025 年向股東回饋近 48 億美元。在此過程中,我們也維持了在同業中名列前茅的資本報酬率與最低資本成本之一的地位。

  • 2025 also marked three significant milestones for Aflac. The 70th year since the company's founding, the 30th anniversary of what is now Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, and the 25th anniversary of the Aflac Duck. Each of these noteworthy milestones demonstrate the staying power of the financial protection Aflac's products help provide and the privilege of helping enrich the lives of millions of people.

    2025 年也標誌著 Aflac 的三項重要里程碑。包括公司成立 70 週年、現今的亞特蘭大兒童醫療保健機構(Children's Healthcare of Atlanta)之 Aflac 癌症與血液疾病中心成立 30 週年,以及 Aflac Duck 25 週年。這些值得紀念的里程碑,展現了 Aflac 產品所協助提供之財務保障的長久生命力,以及我們有幸協助豐富數百萬人生活的榮幸。

  • In today's complex health care environment, our relevant products, financial strength, powerful brand and broad distribution network uniquely positions Aflac as the ideal partner for consumers as they navigate the financial strain from out-of-pocket medical costs, the enduring foundational strengths of our business and our capacity for continued growth in Japan and the US, two of the largest life insurance markets in the world, support our leading position and build on our momentum.

    在當今複雜的醫療保健環境中,我們相關的產品、雄厚的財務實力、強大的品牌以及廣泛的分銷網絡,使 Aflac 具備獨特優勢,成為消費者在面對自付醫療費用所帶來的財務壓力時的理想合作夥伴。我們業務長期且持久的基礎優勢,以及在日本與美國(全球兩大壽險市場)持續成長的能力,支撐我們的領先地位並延續我們的成長動能。

  • I will now turn the program over to Max to cover more details of the financial results. Max?

    接下來我把節目交給 Max,請他說明更多財務結果的細節。Max?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • Thank you, Dan. For the fourth quarter of 2025, adjusted earnings per diluted share increased 0.6% year-over-year to $1.57, excluding effect of foreign currency in the quarter. In this quarter, remeasurement gains on reserves totaled $36 million, reducing benefits. Variable investment income ran $12 million below our long-term return expectations. Adjusted book value per share, excluding foreign currency remeasurement, increased 0.5%.

    謝謝你,Dan。2025 年第四季,排除本季外幣影響後,稀釋後每股調整後盈餘較去年同期增加 0.6% 至 1.57 美元。本季,準備金重新衡量收益合計 3,600 萬美元,降低了給付(benefits)。變動型投資收益較我們長期報酬預期少 1,200 萬美元。每股調整後帳面價值(排除外幣重新衡量)增加 0.5%。

  • The adjusted ROE was 11.7% and 14.5%, excluding foreign currency remeasurement, a solid spread to our cost of capital. Overall, we view these results in the quarter as solid. Starting with our Japan segment. Net earned premiums in Yen terms for the quarter declined 1.9%. The Aflac Japan's underlying earned premiums, which excludes the impact of deferred profit liability, paid out policies and reinsurance declined 1.2%.

    調整後 ROE 為 11.7%;若排除外幣重新衡量則為 14.5%,相較我們的資本成本仍有穩健利差。整體而言,我們認為本季結果表現穩健。先從日本事業部開始。以日圓計,本季淨已賺保費年減 1.9%。Aflac 日本的核心已賺保費(排除遞延利潤負債、已給付保單及再保影響)年減 1.2%。

  • We believe this metric provides a clear insight into long-term premium trends. Japan's total benefit ratio came in at 65% for the quarter, down 150 basis points year-over-year. We estimate the impact from the reserve remeasurement gains to be approximately 110 basis points favorable to the benefit ratio in Q4 2025.

    我們認為此指標能清楚反映長期保費趨勢。日本本季總給付率為 65%,較去年同期下降 150 個基點。我們估計,2025 年第四季準備金重新衡量收益對給付率的影響約為有利 110 個基點。

  • Long-term experience trends as they relate to treatments of cancer and hospitalization continue to be in place, leading to continued favorable underwriting experience. Persistency remained solid year-over-year and in line with our expectations at 93.1%.

    與癌症治療及住院相關的長期經驗趨勢仍然延續,帶來持續有利的核保經驗。保單持續率(persistency)較去年同期仍維持穩健,並符合我們預期,為 93.1%。

  • With refreshed product introductions, we generally see an uptick in lapse and reissue activity, causing reported lapsation to increase. We did experience this uptick with our recently launched cancer insurance product, but overall lapses remain within our expectations. Lapses on our first sector savings block remained low and in line with previous periods despite the increase in yen interest rates.

    隨著新產品推出,我們通常會看到解約與重新投保活動增加,導致報告的解約率上升。我們近期推出的癌症保險產品確實出現這樣的上升,但整體解約仍在我們預期範圍內。儘管日圓利率上升,我們第一部門(first sector)儲蓄型保單組合的解約仍維持偏低,並與先前期間一致。

  • Our expense ratio in Japan was 22% for the quarter, up 120 basis points year-over-year, driven primarily by sales promotion expenses associated with higher sales. For the quarter, adjusted net investment income in yen terms was down 3.9%, primarily driven by lower floating rate income on our US dollar book and lower variable investment income partially offset by higher US dollar fixed income due to higher volume. The pre-tax margin for Japan in the quarter was 31.3%, down 30 basis points year-over-year, a very good result.

    日本本季費用率為 22%,較去年同期上升 120 個基點,主要由於銷售增加所帶動的銷售推廣費用。本季以日圓計的調整後淨投資收益下降 3.9%,主要因我們美元資產組合的浮動利率收益下降,以及變動型投資收益降低;部分被美元固定收益因規模增加而上升所抵銷。日本本季稅前利潤率為 31.3%,較去年同期下降 30 個基點,仍是非常好的結果。

  • Now turning to US results. Net earned premiums were up 4%, while premium persistency declined slightly by 10 basis points year-over-year. It remains strong at 79.2%. Our total benefit ratio came in at 48.6%, 230 basis points higher than Q4 2024, driven by prior year endorsements and higher claims activity on our individual voluntary block as well as a higher benefit ratio on group life and disability. We estimate that reserve remeasurement gains impacted a benefit ratio by approximately 140 basis points in the quarter.

    接著看美國的結果。淨已賺保費成長 4%,而保費持續率較去年同期小幅下降 10 個基點。持續率仍然強勁,為 79.2%。本季總給付率為 48.6%,較 2024 年第四季高 230 個基點,主要受前一年度批單(endorsements)影響,以及個人自願型保單組合的理賠活動增加,並且團體壽險與失能險的給付率也較高。我們估計準備金重新衡量收益對本季給付率的影響約為 140 個基點。

  • Our expense ratio in the US was 40.4%, up 10 basis points year-over-year, primarily driven by timing of spend from previous quarters. Our growth initiatives, group life and disability, network dental and vision and direct-to-consumer increased the expense ratio by 60 basis points in the quarter. This is in line with our expectations, as these businesses continue to scale. Adjusted net investment income in the US was down 2.8% for the quarter, primarily driven by a reduction in floating rate assets and corresponding rates.

    美國本季費用率為 40.4%,較去年同期上升 10 個基點,主要由於前幾季支出時點的影響。我們的成長計畫——團體壽險與失能險、網絡牙科與視力,以及直達消費者(direct-to-consumer)——使本季費用率增加 60 個基點。這符合我們的預期,因為這些業務仍在擴張規模。美國本季調整後淨投資收益下降 2.8%,主要因浮動利率資產規模下降及相應利率變動所致。

  • Profitability in the US segment was solid with a pretax margin of 17.4%, a 230-basis point decrease compared with a stronger quarter a year ago. In Corporate and Other, we recorded a pretax adjusted loss of $31 million in the quarter. Total premiums decreased on closed blocks of business. Adjusted net investment income was $1 million higher than last year due to a combination of lower volume of tax credit investments and higher asset balances.

    美國事業部獲利能力穩健,稅前利潤率為 17.4%,較去年同期較強的一季下降 230 個基點。在「公司及其他」項下,我們本季錄得稅前調整後虧損 3,100 萬美元。已停止承作(closed blocks)的業務保費總額下降。調整後淨投資收益較去年增加 100 萬美元,原因是稅額抵免投資(tax credit investments)規模下降與資產餘額增加的綜合影響。

  • Our tax credit investments impacted a net investment income line for US GAAP purposes negatively by $43 million in the quarter, with an associated credit to the tax line. The total fourth quarter earnings benefit from tax credit investments was $13 million. Adjusted earnings declined due to lower revenues and higher adjusted expenses driven primarily by higher costs pertaining to business operations and higher interest expense, partially offset by lower net benefits in claims. We continue to be pleased with the performance of our investment portfolio.

    就美國 GAAP 而言,我們的稅額抵免投資使本季淨投資收益項目減少 4,300 萬美元,並在稅負項下有相對應的抵減。本季稅額抵免投資對盈餘的總體貢獻為 1,300 萬美元。調整後盈餘下降,原因是收入較低且調整後費用較高,主要由於與業務營運相關成本上升及利息費用增加;部分被理賠淨給付降低所抵銷。我們仍對投資組合的表現感到滿意。

  • During the quarter, we did not record any charge-offs for the commercial real estate portfolio. Additionally, we did not foreclose on any properties in the period. On our portfolio of first lien senior secured middle market loans, we recorded charge-offs of $22 million in the quarter. For US statutory, we recorded a $3 million valuation allowance on mortgage loans as an unrealized loss during the quarter.

    本季我們的商用不動產投資組合未認列任何沖銷(charge-offs)。此外,本期間我們也未對任何物件進行法拍(foreclose)。在第一順位留置權(first lien)的高級擔保中型市場貸款組合方面,我們本季認列 2,200 萬美元的沖銷。就美國法定(US statutory)口徑而言,我們本季對抵押貸款認列 300 萬美元的估值備抵(valuation allowance),作為未實現損失。

  • On a Japan FSA basis, there were net realized gains of JPY380 million for securities impairments in Q4, and we booked a valuation allowance of JPY87 million related to transitional real estate loans. This is well within our expectations and has a limited impact on regulatory earnings and capital.

    以日本金融廳(Japan FSA)口徑,本季因證券減損產生的已實現淨收益為 3.8 億日圓,且我們就過渡性不動產貸款提列 8,700 萬日圓的估值備抵。這完全在我們預期之內,對監理盈餘與資本的影響有限。

  • In the third quarter of 2025, we enhanced our liquidity and capital flexibility by $2 billion with the creation of two off-balance sheet pre-capitalized trust that issued securities commonly referred to as PCAPs. With increased off-balance sheet capital resources and improved liquidity flexibility, we have lowered our minimum liquidity balance at the holding company by $750 million to $1 billion.

    在 2025 年第三季,我們透過設立兩個表外預先資本化信託(off-balance sheet pre-capitalized trust)並發行通常稱為 PCAPs 的證券,使流動性與資本運用彈性增加 20 億美元。隨著表外資本資源增加及流動性彈性提升,我們已將控股公司最低流動性餘額下調 7.5 億美元至 10 億美元。

  • This means that Aflac Inc. unencumbered liquidity stood at $4.1 billion, which was $3.1 billion above our minimum balance at the end of the quarter. The full PCAP facility remains undrawn. Our adjusted leverage was 21.4% for the quarter, which is within our target range of 20% to 25%. As we hold approximately 63% of our debt in yen, this leverage ratio is impacted by moves in the yen-dollar exchange rate. This is intentional and part of our enterprise hedging program, protecting the economic value of Aflac Japan in US dollar terms.

    這表示 Aflac Inc. 的未受限制流動性為 41 億美元,於季末較我們的最低餘額高出 31 億美元。PCAP 額度仍未動用。本季調整後槓桿比率為 21.4%,落在我們 20% 至 25% 的目標區間內。由於我們約 63% 的債務以日圓計價,該槓桿比率會受到日圓兌美元匯率變動影響。這是刻意為之,亦是我們企業避險計畫的一部分,用以在美元口徑下保護 Aflac 日本的經濟價值。

  • Our capital position remains strong. We ended the quarter with an SMR above 970% and an estimated regulatory ESR with the undertaking specific parameter or USP, of 253%. We estimate that the USP benefits the regulatory ESR by 18 points. We estimate our combined RBC to be 575%.

    我們的資本部位仍然強勁。本季末 SMR 超過 970%,且估計監理 ESR(採用承作特定參數或 USP)為 253%。我們估計 USP 使監理 ESR 受益 18 個點。我們估計合併 RBC 為 575%。

  • These are strong capital ratios, which we actively monitor, stress, and managed to withstand market volatility and credit cycles as well as external shocks. We last updated our ESR sensitivities at our financial analysts briefing in December 2024. Since then, we have seen significant movements in both the dollar-yen and yen interest rates. So we wanted to provide an updated estimates before the ESR comes into effect on March 31.

    這些都是強勁的資本比率,我們會主動監控並進行壓力測試,且已妥善管理,使其能夠承受市場波動與信用循環,以及外部衝擊。我們上一次更新 ESR 敏感度是在 2024 年 12 月的金融分析師簡報會上。自那時以來,我們已看到美元兌日圓以及日圓利率都有顯著波動。因此,我們希望在 ESR 於 3 月 31 日生效之前,提供更新後的估計。

  • We have deliberately improved our ALM during this time, which has led to reduced exposure to interest rate risk. We generally have lowered our sensitivities to market risk factors. We've also refreshed the sensitivity analysis related to our combined RBC ratio in the US. I will characterize these refreshed estimates also as being in line with what we shared at Fab in December 2024.

    在此期間,我們刻意改善了資產負債管理(ALM),使利率風險曝險降低。整體而言,我們已降低對市場風險因子的敏感度。我們也更新了與美國合併 RBC 比率相關的敏感度分析。我也會將這些更新後的估計描述為與我們在 2024 年 12 月 FAB 所分享的內容一致。

  • Given the strength of our capital and liquidity, we repurchased $800 million of our own stock and paid dividends of $303 million in Q4, offering good relative IRR on these capital deployments. We will continue to be flexible and tactical in the way we manage the balance sheet and deploy capital in order to drive strong risk-adjusted ROE with a meaningful spread to our cost of capital.

    鑑於我們資本與流動性的強勁,我們在第四季回購了 8 億美元自家股票,並支付了 3.03 億美元股利,這些資本運用帶來了良好的相對 IRR。我們將持續以彈性且戰術性的方式管理資產負債表並配置資本,以推動強勁的風險調整後 ROE,並與資本成本維持具意義的利差。

  • Before concluding, I would like to address our 2026 outlook. At our 2024 financial analyst briefing, I provided ranges for net earned premiums, benefits and expense ratios and pretax profit margin for each segment for 2025 through 2027. These ranges remain substantially intact for 2026, but with a couple of exceptions.

    在結束之前,我想談談我們對 2026 年的展望。在 2024 年金融分析師簡報會上,我針對 2025 至 2027 年各事業部門的淨已賺保費、給付與費用率,以及稅前利潤率提供了區間。這些區間在 2026 年大致維持不變,但有幾個例外。

  • For Aflac Japan, we expect underlying earned premiums to decline 1% to 2% in 2026. We also expect the expense ratio to be in the 20% to 23% range. However, we expect the benefit ratio in Japan to be in the 60% to 63% range and the pre-tax profit margin to be in the 33% to 36% range. In the US, we continue to expect net earned premium growth to be in the lower end of the 3% to 6% range.

    就 Aflac 日本而言,我們預期 2026 年基礎已賺保費將下滑 1% 至 2%。我們也預期費用率將落在 20% 至 23% 的區間。不過,我們預期日本的給付率將落在 60% 至 63% 的區間,稅前利潤率將落在 33% 至 36% 的區間。在美國,我們仍預期淨已賺保費成長將位於 3% 至 6% 區間的較低端。

  • We also expect the benefit ratio for 2026 to be in the 48% to 52% range and the expense ratio to be in the 36% to 39% range as we continue to scale new business lines. At the same time, we expect pretax profit margin for 2026 to be in the range of 17% to 20%.

    我們也預期 2026 年給付率將落在 48% 至 52% 的區間,費用率將落在 36% 至 39% 的區間,因為我們持續擴大新業務線的規模。同時,我們預期 2026 年稅前利潤率將落在 17% 至 20% 的區間。

  • Thank you. I will now turn the call back over to David for Q&A.

    謝謝。我現在把電話交回給 David 進行問答。

  • David Young - Vice President - Capital Markets

    David Young - Vice President - Capital Markets

  • Thank you, Max. (Event Instructions)

    謝謝你,Max。(活動說明)

  • Operator

    Operator

  • And ladies and gentlemen, we'll now begin that question-and-answer session. (Operator Instructions)

    各位女士、先生,我們現在開始問答環節。(接線員指示)

  • Wes Carmichael, Wells Fargo.

    Wes Carmichael,富國銀行。

  • Wes Carmichael - Analyst

    Wes Carmichael - Analyst

  • I had a question on the Japan business. And Max, I think you touched on this a little bit in your prepared remarks. But in particular, in the savings products ways per sector, we've seen super loan yields in Japan rise pretty considerably. And I think more broadly, there's some concern that we could see additional, I guess, surrenders with interest-sensitive products. So curious if you expect higher levels of surrender going forward? I know that was pretty stable recently.

    我有一個關於日本業務的問題。Max,我想你在事先準備的發言中有稍微提到。但特別是,在儲蓄型產品方面(按產品類別來看),我們看到日本的超長期債券殖利率上升得相當明顯。而更廣泛地說,市場也有些擔憂,利率敏感型產品可能會出現更多(我想是)解約。所以想請教你是否預期未來解約水準會更高?我知道最近其實相當穩定。

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • Thank you, Wes, for the question. Yes, obviously, we've seen quite significant moves up, especially at the long end of the young yield curve lightly. And if everybody is 100% efficient in their behavior, you would expect both demand and potentially a lapsation of in-force policies to increase somewhat. We have not experienced that yet, but obviously, it's something that we closely monitor and prepare the company for it.

    謝謝你,Wes,提出這個問題。是的,很明顯我們看到利率有相當顯著的上行變動,尤其是日圓殖利率曲線的長端近期上升。如果每個人的行為都 100% 有效率,你會預期需求以及可能的在保保單脫落率(lapse)都會有所上升。我們目前尚未經歷這種情況,但這顯然是我們密切監控並為公司預作準備的事項。

  • Wes Carmichael - Analyst

    Wes Carmichael - Analyst

  • Got it. And my follow-up is just on capital. It seems like you've got a lot of flexibility in terms of regulatory solvency in Japan and the US. But also at the parent 2, and you continue to be pretty tactical with the buyback. But curious, if once ESR is printed in 2026, is there any change to the thinking around M&A or capital deployment just given the capital flexibility you have? And maybe what could be incremental for you?

    了解。我的追問是關於資本。看起來你們在日本與美國的監理清償能力方面都有很大的彈性。而且在母公司層級也是如此,你們也持續在回購上採取相當戰術性的作法。但我想問的是,一旦 ESR 在 2026 年公布後,考量你們的資本彈性,對於併購或資本配置的想法是否會有任何改變?以及對你們而言,可能有哪些額外的增量機會?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • From a capital standpoint, we've been traveling with significant capital for quite some time, and we continue to both enhance and increase the flexibility of both the sources and how we can use that as well. When it comes to M&A, that's predominantly an operational and strategic question, and that secondarily is a financial question.

    就資本而言,我們長期以來一直維持相當充裕的資本水位,並且持續提升與增加資本來源的彈性,以及我們可如何運用這些資本的彈性。至於併購(M&A),那主要是營運與策略面的問題,其次才是財務面的問題。

  • So the way we evaluate M&A, it really goes through those lenses, and it needs to tick all those boxes. But the fact of the matter is, do we have capital available if we wanted to do something? That is absolutely true.

    因此,我們評估併購的方式確實會透過這些角度來檢視,而且必須符合所有條件。但事實是,如果我們想做某些事情,我們是否有可用資本?答案絕對是有的。

  • But I would also acknowledge that we are operating in a relatively narrow niche, both in the United States and in Japan and to sort of find operational and strategic targets within those niches is relatively difficult to find. So we continue to obviously evaluate things. But for the time being, we're very happy with the businesses that we have.

    但我也要承認,我們在美國與日本都處於相對狹窄的利基市場,要在這些利基中找到符合營運與策略的標的,相對而言並不容易。因此我們當然會持續評估各種機會。但就目前而言,我們對現有的業務組合非常滿意。

  • Operator

    Operator

  • John Barnidge, Piper Sandler.

    John Barnidge,Piper Sandler。

  • John Barnidge - Analyst

    John Barnidge - Analyst

  • My question is around Japan. Can you maybe talk about the lower benefit ratio indebted in the guidance, and I think it's based on Japan new business versus the in-force block. I know there's been some repricing and new products being introduced. But how enduring does that benefit seem to be?

    我的問題是關於日本。你能否談談指引中較低的給付率(benefit ratio)背後的原因?我認為這是基於日本新契約相對於在保保單組合。我知道你們做了一些重新定價,也推出了新產品。但這樣的給付率改善看起來有多持久?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • Thank you, John. So there's a couple of factors that is pushing our benefit ratio down on a GAAP basis in 2026. The first one, I would put in a more permanent category, and that is -- as we updated our actuarial assumptions in the third quarter of 2025, we lowered the net premium ratio by about 130 basis points.

    謝謝你,John。因此,有幾個因素在 2026 年以 GAAP 基礎推動我們的給付率下降。第一個我會歸類為較為永久性的因素,也就是——在我們於 2025 年第三季更新精算假設時,我們將淨保費比率下調了約 130 個基點。

  • That is for the full in-force block and that it was obviously a one-timer in the third quarter, but it also feeds through into the future net premium ratio as well. So that is directly impacting the benefit ratio for future period by 130 basis points lower, all things being equal.

    這是針對整個在保保單組合;這在第三季顯然是一次性的調整,但也會反映到未來的淨保費比率之中。因此,在其他條件不變下,這會直接使未來期間的給付率降低 130 個基點。

  • The other impact is with new product introductions that we've seen on our cancer product. And as we now introduce our medical product, we've seen an elevation of lapse and reissue activity when those product introductions take place.

    另一個影響來自我們在癌症險產品上的新產品推出。而隨著我們現在推出醫療險產品,在這些產品推出時,我們看到解約與重新投保(lapse and reissue)活動有所增加。

  • When you have lapse and reissue increase, the old policies that lapses, we will then release the reserves associated with those policies and it runs through our GAAP financials, lowering the benefit ratio. And generally speaking, we have lower reserves on our older policies than the new policies that we are reissuing. So that also has an impact for us.

    當解約與重新投保增加時,對於解約的舊保單,我們會釋放與這些保單相關的準備金,並反映在我們的 GAAP 財報中,從而降低給付率。一般而言,我們舊保單的準備金低於我們正在重新承保(reissue)的新保單。因此,這也會對我們造成影響。

  • The last piece is -- if you go back and analyze our full in-force, we did sell quite a lot of life insurance savings policies in the years 2010 through 2016, and this is the old waste product. That waste product runs through our GAAP financials with a very high benefit ratio. On an economic basis, it carries a significantly lower benefit ratio. But on a GAAP basis, it's very high.

    最後一塊是——如果你回頭分析我們整體在保保單(in-force),我們在2010年至2016年間確實銷售了相當多的壽險儲蓄型保單,而這就是那批舊的「廢料」產品。這批「廢料」在我們的GAAP財報中呈現非常高的給付比率。以經濟基礎來看,它的給付比率顯著較低。但以GAAP基礎來看,它非常高。

  • That block obviously is in runoff. And as that block shrinks, then obviously, the mix impact is such that our total benefit ratio is then lower. So I will characterize those three factors as the main factors for the lower benefit ratio expected in 2026.

    那個保單組合顯然正處於自然消退(runoff)。而隨著該組合縮小,組合結構的影響也很明顯,使得我們的總給付比率就會降低。因此,我會把這三個因素描述為2026年預期給付比率較低的主要原因。

  • John Barnidge - Analyst

    John Barnidge - Analyst

  • Thanks, Max. And my related follow-up, sticking with Japan on distribution. It looks a lot like Tsumitasu got repriced and Anshin Palette got introduced. Can you talk about what you see as the total addressable market for these new products? And then within the context of Miraito and ability, do you need to reprice that?

    謝謝,Max。我有一個相關的追問,仍然聚焦在日本的通路。看起來Tsumitasu已經重新定價,而Anshin Palette也已推出。你能談談你認為這些新產品的整體可觸及市場(TAM)有多大嗎?另外,在Miraito與能力(ability)的脈絡下,你們需要重新定價嗎?

  • Koichiro Yoshizumi - Executive Vice President, Sales & Marketing

    Koichiro Yoshizumi - Executive Vice President, Sales & Marketing

  • (interpreted) This is Yoshizumi speaking from Marketing and Sales division of Aflac Japan. As you mentioned, we went through a rate revision last September. And since then, sales are growing steadily. And the purpose of launching Tsumitasu is to respond to the citizens' needs of asset formation as the government is also promoting people to shift from savings to investment. So we -- our purpose was to encourage those young and middle-aged generation to promote such activities.

    (口譯)我是Aflac日本行銷與銷售部門的Yoshizumi。如你所提到,我們在去年9月進行了費率修訂。此後,銷售穩健成長。推出Tsumitasu的目的,是回應民眾資產形成的需求,因為政府也在推動民眾從儲蓄轉向投資。因此,我們——我們的目的,是鼓勵年輕與中壯年族群推動這類活動。

  • So our market audience will be those -- the individual customers who seek for yen-denominated level payment products. But in fact, actually, Tsumitasu is also gaining popularity from middle age to older generation. This is a result from gaining attention and clarity from affluent customers who prefer to pay with that or discounted advanced premium option.

    因此,我們的目標市場受眾將是——尋求日圓計價、等額繳費產品的個人客戶。但事實上,Tsumitasu也正受到中年到高齡族群的歡迎。這是因為偏好採用一次繳清或折扣預繳保費選項的高資產客戶,對該產品的關注度與理解度提升所帶來的結果。

  • One of Tsumitasu strength is the fact that we can change the premium rate in a timely manner with agility. So going forward, whenever we see a necessity given the interest rate situation, when time comes, we will increase or decrease our premium rate as necessary. That's all from me.

    Tsumitasu的一項優勢在於,我們能以敏捷方式及時調整保費費率。因此,往後只要在利率環境下我們看到有必要,時機一到,我們就會視需要上調或下調保費費率。我就說到這裡。

  • Daniel Amos - Chairman of the Board, Chief Executive Officer

    Daniel Amos - Chairman of the Board, Chief Executive Officer

  • This is Dan. Let me just make a couple of comments about sales to have a more concise way of you looking at it. Miraito, our newest cancer policy, did terrific, better than we even thought. And we're -- we feel like, it was a product that was wanted and needed by the consumers, and that's what's driving it.

    我是Dan。我想就銷售補充幾點,讓你用更精簡的方式來看。Miraito,我們最新的癌症保單,表現非常出色,甚至超出我們的預期。而我們——我們覺得這是一個消費者想要、也需要的產品,這正是推動它的原因。

  • Saying that, we had enormous sales in 2025. And we would expect sales to be more level, where I think you'll see an increase in sales will be at the medical product. And also, the potential is for Tsumitasu, depending on what interest rates do. But that has the potential. But overall, cumulatively, we expect a good year in Aflac Japan in regard to sales and the job they're doing.

    話雖如此,我們在2025年的銷售非常強勁。而我們預期銷售會更趨於平穩,我認為你會看到醫療產品的銷售增加。另外,Tsumitasu也有潛力,取決於利率走勢。它確實有這樣的潛力。但整體而言,累計來看,我們預期Aflac日本在銷售以及他們所做的工作方面,會有一個不錯的一年。

  • And I want to personally thank all of them on the other end from Japan for the job that they did in 2025 in setting an enormous record for us to work toward again in 2026.

    我也想親自感謝日本那邊的所有同仁,感謝他們在2025年的表現,為我們創下了巨大的紀錄,讓我們在2026年再次以此為目標努力。

  • Operator

    Operator

  • Joel Hurwitz, Dowling & Partners.

    Joel Hurwitz,Dowling & Partners。

  • Joel Hurwitz - Analyst

    Joel Hurwitz - Analyst

  • I wanted to touch on US sales. So the overall growth tracked pretty in line with what you guys saw in the first three quarters of the year. But it looks like the supplemental health growth was better, while disability sales were down. Virgil, can you just talk about what you saw in terms of sales in the quarters? And I guess, any color on how the group life and disability and dental sales were versus expectations?

    我想談一下美國的銷售。整體成長大致與你們在今年前三季看到的趨勢一致。但看起來補充健康險的成長較好,而失能險銷售下滑。Virgil,你能談談你在各季度銷售方面看到的情況嗎?另外,也想請你補充一下團體壽險、失能險與牙科銷售相較於預期的表現如何?

  • Virgil Miller - President, President - Aflac U.S.

    Virgil Miller - President, President - Aflac U.S.

  • Yes. Thank you, Joel. Yes, let me just give an overview of sort of the performance throughout, and I'll give you a little bit more detail on some of the numbers behind the scenes. Again, overall for the year, we did $1.6 billion overall. So I'm pleased with that sales number, how we came out.

    好的。謝謝你,Joel。是的,我先概述一下整體期間的表現,並補充一些幕後數字的細節。再次強調,全年整體我們做到16億美元。所以我對這個銷售數字、以及最終結果感到滿意。

  • And when you asked about the buy-to-bill specifically, they made up 20% of that overall number. So what am I calling the buy-to-bill? Just a reminder, the life absence and disability. And overall, for the year, that line of business was up 11.3%. Network dental and vision, but just a dental product itself a network was up 48.8% for the year.

    你特別問到buy-to-bill,它占了整體數字的20%。那我所說的buy-to-bill是什麼?提醒一下,就是壽險、缺勤(absence)與失能(disability)。而全年來看,這條業務線成長了11.3%。網路型牙科與視力——但單就牙科這個網路型產品而言,全年成長了48.8%。

  • And then our direct-to-consumer platform we refer to as consumer markets was up 10.5%. So that's where I get the combined 20% of total of the $1.6 billion. So overall, I am very pleased with how those businesses performed and a lot of that sales in that life and disability with sales of our life products, to your point. But again, definitely overall good performance.

    接著,我們的直達消費者平台,我們稱之為消費者市場(consumer markets),成長了10.5%。因此,這些加總起來就是16億美元總額中的20%。整體而言,我對這些業務的表現非常滿意,其中相當一部分來自壽險與失能這塊的銷售,尤其是我們壽險產品的銷售,正如你所提。但總之,整體表現確實不錯。

  • The only thing I would say to you is when you look at the year, it was pretty much consistent. We ended up overall 3.1%, but we did have good earned premium growth of 4% during the quarter, right at 2.9% to 3% for the year. Persistency remained strong, 79.2%. So when I look at the overall look at a good, solid balance performance for the year for us.

    我唯一想補充的是,從全年來看,表現相當一致。我們整體最後是成長3.1%,但本季的已賺保費(earned premium)成長良好,達4%;全年大約在2.9%到3%。保單持續率(persistency)仍然強勁,為79.2%。所以整體來看,我認為我們今年的表現是良好、穩健且平衡的。

  • Joel Hurwitz - Analyst

    Joel Hurwitz - Analyst

  • Okay. Great. And then, Max, just a quick one on ESR. In your prepared remarks, you had said that the uplift from the USP was 18 points. I think the last time you disclosed it a couple of quarters ago, it was 30 points. Can you just take us through the drivers of the decline in that?

    好的。很好。接著,Max,關於ESR我有個簡短問題。在你準備好的發言中,你提到USP帶來的提升是18個點。我記得你們上次在幾個季度前披露時是30個點。你能帶我們了解一下,這個提升幅度下降的驅動因素是什麼嗎?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • The main driver of that decline is related to the level of yen interest rates. So as yen interest rates go higher, the impact from the USP tends to -- will decline a little bit.

    這個下降的主要驅動因素與日圓利率水準有關。因此,隨著日圓利率走高,USP帶來的影響往往——會略為下降一些。

  • Operator

    Operator

  • Jack Matten, BMO.

    Jack Matten,BMO。

  • Jack Matten - Analyst

    Jack Matten - Analyst

  • I just had one follow-up on the Japan benefit ratio. Any way for us to think about the kind of the statutory or economic margin change that you're seeing? I know there's different dynamics between how the ways product accounting works, and there's -- the net premium ratio change is also a big driver. But the GAAP update -- but just wondering, putting all together, you still seeing a better trend on a statutory margin basis?

    我還有一個關於日本給付比率的追問。我們可以如何思考你們看到的法定或經濟利差(margin)變化?我知道產品會計處理方式不同,動態也不一樣,而且淨保費比率(net premium ratio)的變動也是一個很大的驅動因素。但GAAP更新——只是想問,把這些都放在一起看,你們在法定利差基礎上仍然看到更好的趨勢嗎?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • Yes. So the main difference between the benefit ratio and the US GAAP benefit ratio, it relates to the net premium ratio. So what I referenced there was that the net premium ratio on a US GAAP basis will lower our benefit ratio by roughly 130 basis points in 2026 relative to the first three quarters of 2025.

    是的。因此,給付率與美國 GAAP 給付率之間的主要差異,與淨保費比率有關。我剛才提到的是,以美國 GAAP 為基礎的淨保費比率,將使我們在 2026 年相較於 2025 年前三季的給付率大約降低 130 個基點。

  • That impact will not occur on an FSA earnings basis, but the other drivers will. So think about it this way that essentially, when you look at the decline in the benefit ratio in 2026 over 2025, about one-third of that is driven by the lower net premium ratio. The other two-thirds will occur both on a US GAAP basis and on an FSA earnings basis.

    這項影響不會在 FSA 盈餘基礎下發生,但其他驅動因素會。所以可以這樣理解:基本上,當你看 2026 年相較 2025 年給付率的下降時,其中約三分之一是由較低的淨保費比率所驅動。另外三分之二則會同時出現在美國 GAAP 基礎與 FSA 盈餘基礎下。

  • Jack Matten - Analyst

    Jack Matten - Analyst

  • That's helpful. And then just a follow-up on the -- on your Bermuda entity. I mean, any change to your kind of outlook and how you expect to use that entity over time? I know you've kind of talked in the past about reinsuring up to 10% of your in-force in Japan. Is that limit something you're still evaluating? Or could it be revised higher over time?

    這很有幫助。接著再追問一下——關於你們的百慕達實體。我的意思是,你們對該實體的展望,以及預期隨時間如何使用它,有沒有任何改變?我知道你們過去曾談到,會將日本在保業務最多約 10% 進行再保。這個上限你們仍在評估嗎?或者未來是否可能上修?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • Yes. So to date, we've seen that roughly 6% of our Aflac Japan balance sheet to Bermuda. We have a midterm target to get to 10%. We do not think of that as an absolute limit. I think over time, we will risk assess that number and evaluate if there's a higher internal limit that would make sense for us. The bottom line is that we see significant capacity for continuing seeding business between our subsidiary in Japan and our reinsurance affiliate in Bermuda.

    是的。截至目前,我們大約已將 Aflac 日本資產負債表的 6% 轉到百慕達。我們的中期目標是達到 10%。我們不把那視為絕對上限。我想隨著時間推進,我們會對該數字進行風險評估,並評估是否存在更高、對我們而言合理的內部上限。重點是,我們看到在日本子公司與百慕達再保關係企業之間持續分出業務(seeding business)的顯著承接容量。

  • Operator

    Operator

  • Suneet Kamath, Jefferies.

    Suneet Kamath,Jefferies。

  • Suneet Kamath - Equity Analyst

    Suneet Kamath - Equity Analyst

  • That was helpful color on the Japan benefit ratio, Max. I appreciate that. Just wondering if you could maybe do the same for the US benefit ratio because the guide is 48% to 52%, I believe. And it looks like you've been traveling kind of more in the mid-40% range. So I don't know if you're assuming some reversion to the mean or something, but just some color on that would be helpful.

    Max,你對日本給付率的補充說明很有幫助。我很感謝。想請問你是否也能對美國給付率做類似說明,因為指引我記得是 48% 到 52%。而看起來你們一直比較落在 40% 中段。所以我不確定你們是否假設會回歸均值之類的,但若能補充一些背景會很有幫助。

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • So there's a couple of factors going on impacting the benefit ratio in the US. And some of them are for specific lines of business, and some of it is driven by mix of business as well. So we have, as outlined in the script, we have actively increased the benefit ratios on a number of products, utilizing endorsements, also increasing benefits. This applies specifically to our cancer product in the US on an individual basis.

    美國的給付率受到幾個因素影響。其中一些是特定業務線的因素,另一些也由業務組合所驅動。如講稿所述,我們已透過附加條款(endorsements)以及提高給付,主動提高多項產品的給付率。這特別適用於我們在美國的個人癌症保險產品。

  • It also applies to our accident policy. These products were running very low during the pandemic due to low claims utilization, and we have actively gone in and increased those future benefit ratios associated with those products. So that in itself will continue to push our benefit ratio slightly higher.

    這也適用於我們的意外險保單。這些產品在疫情期間因理賠使用率偏低而處於非常低的水準,我們已主動介入,提高與這些產品相關的未來給付率。因此,單就這點本身,將會持續使我們的給付率略為上升。

  • At the same time, when you look at the total benefit ratio, there's a mix impact as well. Virgil just outlined that the sales of group life and disability and dental and vision specifically are increasing quite significantly for us. These businesses are gradually becoming an increased proportion of our total in-force and they carry a higher benefit ratio than our core voluntary benefits products.

    同時,當你看整體給付率時,也存在組合效應。Virgil 剛才提到,我們的團體壽險、失能險,以及牙科與視力保險的銷售都在相當顯著地成長。這些業務逐步在我們的整體在保業務中占比提高,而它們的給付率也高於我們核心的自願性福利產品。

  • So what that means is that over time, that mix impact will move our benefit ratio slightly higher as well. And you see some of that happening in 2026.

    這代表隨著時間推進,這種組合效應也會使我們的給付率略為上升。你會在 2026 年看到其中一部分正在發生。

  • Suneet Kamath - Equity Analyst

    Suneet Kamath - Equity Analyst

  • Okay. Got it. And then I guess maybe for Virgil or Dan, we're hearing a lot more about this sort of K-shaped economy and sort of given your target market. Just wondering what sort of impact do you expect in terms of both consumer behavior, but also in terms of agent recruiting potential?

    好的。了解。接著我想可能問 Virgil 或 Dan:我們聽到很多關於所謂 K 型經濟的討論,考量你們的目標市場。想請問你們預期會帶來哪些影響,包括消費者行為,以及業務員招募潛力方面?

  • Virgil Miller - President, President - Aflac U.S.

    Virgil Miller - President, President - Aflac U.S.

  • Yes. This is Virgil. Let me start -- let me work backwards to understand which you just said about the age of recruiting. So first, I would say, we were up for the year with our career recruiting. To your point, on the environment, we certainly monitor inflationary rates. We monitor unemployment rate. We look at any material impact. Of course, we look at anything related to interest rates in US dollar rates. But I can't tell you right now to have any material impact on us this year.

    是的。我是 Virgil。我先從——我先倒著說,先回到你剛才提到的招募。首先我會說,我們今年的專職通路招募是成長的。如你所說,針對環境面,我們確實會監控通膨率。我們監控失業率。我們會觀察是否有任何重大影響。當然,我們也會關注任何與利率、美元利率相關的事項。但就目前而言,我無法告訴你今年對我們有任何重大影響。

  • What we did was we put a deliberate focus on our career channel. We are dedicated and still believe in the agency force that we have out there. We increased it this year in new recruits. We were able to have a higher conversion rate than we normally have. So 16% of those converted into sellers as we go through that process.

    我們所做的是對專職通路進行有意識的聚焦。我們致力於、也仍然相信我們在外的業務員隊伍。今年我們的新招募人數增加了。我們也能達到比平常更高的轉換率。因此在流程推進中,有 16% 轉換為實際銷售人員。

  • And then the last thing I'd say is, we increased the productivity. So I totally agree with you that there's a volatility in the market, if you look at these lands, but they had no material impact on us.

    最後我想說的是,我們提升了生產力。所以我完全同意你所說,若看這些面向,市場確實存在波動,但它們對我們沒有任何重大影響。

  • The other thing I would point out too, though, is that we're also looking at things that we can do to make sure that consumers get access to our products. You see us continue to be dedicated to making sure we have a strong brand out in the market.

    另外我也想指出,我們同時也在看有哪些事情可以做,以確保消費者能取得我們的產品。你會看到我們持續致力於確保在市場上維持強勢品牌。

  • We know that there were some changes this year, about 22 million Americans were affected by ACA. We still sell our products alongside major medical. We do not want to see people go uninsured, but you need to get a major medical plan alongside our supplemental health. And we did see an increase, though, in activity coming from that group going through our direct rate consumer channel. So we want to make sure that we offer our products however people need to get access to them. And we did have a 10.5% increase in that channel itself.

    我們知道今年有一些變化,大約有 2,200 萬名美國人受到 ACA 影響。我們仍然在主要醫療保險(major medical)旁邊銷售我們的產品。我們不希望看到人們沒有保險,但你需要在我們的補充健康保險之外,同時搭配一個主要醫療計畫。而我們確實看到,來自該族群、透過我們直效面向消費者通路(direct-to-consumer channel)的活動有所增加。因此我們希望確保,不論人們需要用什麼方式取得,我們都能提供產品。而該通路本身我們也有 10.5% 的成長。

  • So overall, I would tell you, no material impact. We are certainly making sure that our distribution is still network through our agency force. We remain dedicated to it throughrecruitment and conversion. We have strong relationships with our broker channel. Again, we continue to see increases in broker sales and group sales year-over-year-over-year. So Dan, any further comment?

    整體而言,我會告訴你,沒有重大影響。我們當然也確保,我們的配銷仍然是透過我們的業務員隊伍所構成的網絡。我們透過招募與轉換持續投入。我們與經紀通路也有很強的關係。同樣地,我們持續看到經紀銷售與團體銷售年增、年增、再年增。所以 Dan,你還有要補充的嗎?

  • Daniel Amos - Chairman of the Board, Chief Executive Officer

    Daniel Amos - Chairman of the Board, Chief Executive Officer

  • I think we're expecting 2026 to be a good year for us, and we're looking forward.

    我想我們預期 2026 年對我們會是很好的一年,我們也很期待。

  • Operator

    Operator

  • Tom Gallagher, Evercore ISI.

    Tom Gallagher,Evercore ISI。

  • Thomas Gallagher - Analyst

    Thomas Gallagher - Analyst

  • First question is back to Virgil on the US. I heard Max's comment that you've had significant increases in group sales. Can you talk about what kind of levels we're talking about here for group versus non-group sales? Yes, I'm just curious because I'm wondering if there's like explosive growth in group, what's happening to your voluntary benefits because the total sales number is still pretty low?

    第一個問題回到美國業務,想問 Virgil。我聽到 Max 的評論說你們團體銷售有顯著增加。你能談談我們這裡所說的團體與非團體銷售大概各是什麼樣的水準嗎?是的,我只是好奇,因為我在想,如果團體有爆發性成長,那你們的自願性福利怎麼了,因為總銷售數字看起來仍然相當低?

  • Virgil Miller - President, President - Aflac U.S.

    Virgil Miller - President, President - Aflac U.S.

  • Yes. Thank you for that question. Yes. So let me start with the voluntary benefits of four traditional products. And remember, we are carrying probably when -- not probably. We're carrying a large block that other competitors just don't have, which is a great thing for Aflac. That block is certainly produced for Aflac many, many years. It delivers high profitability ranges. We are still committed to that mainly driven through our agency force. I want to make sure I state that and we stand committed.

    是的。謝謝你的提問。是的。那我先從四項傳統產品的自願福利開始談。而且請記得,我們承保著可能在——不是可能。我們承保著一大塊其他競爭對手根本沒有的業務,這對 Aflac 來說是件很棒的事。那個業務區塊確實是 Aflac 多年、多年以前就承作的。它帶來很高的獲利區間。我們仍然致力於這塊業務,主要是透過我們的代理人通路來推動。我想確保我把這點講清楚,而且我們會持續堅定投入。

  • We're continuing to enhance our products there with revising our accident and our cancer products in that space. But what you're seeing, though, overall is that our traditional business has been flat to negative for the past for years, including last year.

    我們也持續在那裡強化產品,例如在該領域修訂我們的意外險與癌症險產品。不過你看到的整體情況是,我們的傳統業務在過去幾年(包括去年)一直是持平到負成長。

  • So when you have that anchor of a core business, you don't see the tremendous explosive growth that you are seeing, that we are seeing, though, on the group side. So if you look at isolated just on group policies and products themselves that we file as group benefits, the overall growth would have been 14%. We would have been much higher than the industry or any competition. And going underneath that, I'll be more specific as I can share some of the numbers.

    所以當你有那樣一個作為錨定的核心業務時,你就不會看到那種非常爆發性的成長——而我們在團體端確實看到了那樣的成長。因此如果你只看我們以團體福利申報的團體保單與產品本身,整體成長會是 14%。我們會遠高於產業或任何競爭對手。再往下拆解,我會盡可能具體,分享一些數字。

  • The network dental product is filed as a group benefit. It was up 48.8%. Our life absence disability, if you were to combine that block of business, was up 11.3%. And then the original traditional group benefits we bought, you remember, we purchased Continental American. It's now Aflac Group CAIC. More core VB was up 11.7%. So again, solid growth in the group space, driven by brokers. Our broker relationships are very strong.

    網路牙科產品是以團體福利申報的。成長了 48.8%。我們的人壽、缺勤與失能(如果把那個業務區塊合併來看)成長了 11.3%。然後是我們買下的原本傳統團體福利,你還記得,我們收購了 Continental American。現在是 Aflac Group CAIC。較核心的自願福利(VB)成長了 11.7%。所以再次強調,團體領域有穩健成長,由經紀人推動。我們與經紀人的關係非常強。

  • And then you can see I'm very, very pleased with those numbers. The focus continues to be two things for us. A, we're going to unify those channels though. One of the things that we can do a better job of and we're focused on in 2026 is making sure that group lands that we give one unified experience. We're investing in a unified experience through platform and technology and also how we go to market. And that is one of the things we will continue to work on and deliver.

    而且你也看得出來,我對這些數字非常、非常滿意。我們的重點仍然是兩件事。A,我們會把這些通路整合起來。我們可以做得更好、而且在 2026 年聚焦的一件事,是確保在團體端我們提供一個一致的體驗。我們正透過平台與科技投資於一致化體驗,也包括我們如何進入市場。這是我們會持續努力並交付成果的方向之一。

  • But then the second thing, we're making some additional investment though in the traditional business. We're going to continue to enhance our products. We're going to continue to recruit, but we're also enhancing the technology. We've improved our enrollment platform that we just released in the first quarter of this year, and we're expecting that to be a benefit in that particular channel.

    第二件事是,我們也在傳統業務上做一些額外投資。我們會持續強化產品。我們會持續招募,同時也在強化科技。我們改善了投保/加保(enrollment)平台,並在今年第一季剛發布,我們預期這會在該通路帶來效益。

  • Daniel Amos - Chairman of the Board, Chief Executive Officer

    Daniel Amos - Chairman of the Board, Chief Executive Officer

  • This is Dan. I want to make one other comment, and that is, as we reflect back over the COVID period, and you look at our distribution channel, it wasn't the product that changed things. It was the number of producers out in the field force selling for us. They were pulled away to a degree because it was total commissions and they were shut down and replacing those people has taken some time.

    我是 Dan。我想再補充一點:回顧 COVID 期間,看看我們的通路,其實不是產品改變了局面。而是我們在外勤銷售隊伍中、為我們銷售的業務員(producers)人數。他們在某種程度上被拉走了,因為那段時間是全佣金制、而且業務被迫停擺,補回那些人花了一些時間。

  • But we are having success with that. And we've been working on the quality of the producers and they've been producing at a faster pace than our old new producers. And so that's to give you some context on why that old channel has slowed down. So it's part of recruiting, recruiting, recruiting.

    但我們在這方面是有成果的。我們一直在提升業務員的品質,而他們的產能提升速度比我們過去的新進業務員更快。所以這是給你一些背景,說明為什麼那個舊通路放慢了。所以其中一部分就是招募、招募、再招募。

  • Thomas Gallagher - Analyst

    Thomas Gallagher - Analyst

  • Okay. My follow-up is on Japan. I guess listening, Dan, to you describe the sales outlook in Japan for '26. It sounds pretty good, which follows a very good '25. Curious why that's not translating to better earned premium growth? We're still in that negative 1% to 2% range on a core basis. Are we more likely to see an inflection in 2027?

    好的。我接著想問日本。Dan,聽你描述 2026 年日本的銷售展望,聽起來相當不錯,而這是在 2025 年表現很好的基礎上。我好奇為什麼這沒有轉化為更好的已賺保費成長?以核心基礎來看,我們仍在負 1% 到 2% 的區間。我們是否更可能在 2027 年看到拐點?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • So Tom, it's -- we're somewhat a victim of very strong persistency. So if you think about Japan, it's a very, very, very large in-force block, and the new sales that we're adding each year is relatively small relative to the total in-force block because of the high persistency that we have. So it takes quite some time for increased sales to sort of get to that level where you're really adding growth to the overall in-force block.

    Tom,這——我們某種程度上是非常高的保單持續率(persistency)的「受害者」。所以你想想日本,那是一個非常、非常、非常龐大的在保(in-force)業務區塊;由於我們的持續率很高,我們每年新增的新契約銷售相對於整體在保區塊其實相對小。因此,銷售增加要花相當一段時間,才會累積到真正能對整體在保區塊帶來成長的程度。

  • COVID had a couple of years where our sales dropped quite significantly, and the delta between sales and lapses was significant, and we are closing in on that gap now. And once that turns positive, it's eventually when we are going to have net earned premium growth in Japan. So we see that within a reasonable future. But even going into 2026, we still expect that lapses will be greater than total sales.

    COVID 那幾年我們的銷售曾大幅下滑,而銷售與失效率(lapses)之間的差距很大;我們現在正在逐步縮小那個缺口。一旦那個差距轉為正值,最終我們就會在日本看到淨已賺保費成長。所以我們認為在可預見的未來會發生。但即使進入 2026 年,我們仍預期失效率會高於總銷售。

  • Operator

    Operator

  • Alex Scott, Barclays.

    Alex Scott,Barclays。

  • Alex Scott - Equity Analyst

    Alex Scott - Equity Analyst

  • I just had a follow-up on the Japan premium growth. I know you guided to sort of the underlying growth. But could you talk about any of the more, I guess, non-underlying or non-core parts of it, just so we -- making sure we understand how the guidance kind of looks with the actual premiums that will come in because I know there's some paid-up policies and maybe reinsurance impact. I just want to make sure I have that clear.

    我想追問一下日本保費成長。我知道你們提供了某種「基礎」成長的指引。但你能談談一些比較——我想——非基礎或非核心的部分嗎?這樣我們——確保我們理解指引在實際會進來的保費上會長什麼樣子,因為我知道有一些繳清保單(paid-up policies)以及可能的再保影響。我只是想確認我把這點弄清楚。

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • So in the guidance that we gave on negative 1% to negative 2%, on that metric, just to go back to the fourth quarter, we were at the lower end of that or the better end of it at negative 1.2%. So what we adjust for is the deferred profit liability impacts, any paid-up impact and then also any reinsurance. So if we execute any reinsurance throughout the year, that is not contemplated in that guidance.

    所以我們給的指引是負 1% 到負 2%;就這個指標而言,回到第四季,我們是在那個區間的較低端、或較好的一端,為負 1.2%。我們調整的項目包括:遞延利益負債(deferred profit liability)的影響、任何繳清(paid-up)的影響,以及任何再保。因此如果我們在年度中執行任何再保,那並未納入該指引的考量。

  • So for example, if we were to decide to move any significant block of business seating from Aflac Japan to Aflac Bermuda, then obviously, the net earned premiums is expected to be impacted in Aflac Japan. That being said, those earned premiums would show up in the Bermuda's legal entity instead and show up in the corporate and other segment.

    例如,如果我們決定把任何顯著的業務區塊從 Aflac Japan 轉分出(seating)到 Aflac Bermuda,那麼很明顯,Aflac Japan 的淨已賺保費預期會受到影響。話雖如此,那些已賺保費會改在 Bermuda 的法定實體入帳,並在「公司及其他」部門呈現。

  • So it's just premiums out of one pocket into the other, so to speak. So it wouldn't impact the total premiums for the total enterprise. But the three components that really differs between the net earned premiums that was negative 1.9% in the fourth quarter and the underlying of 1.2%, the vast majority of that is paid-up status, and then a little component of that is the deferred profit liability. There was very little impact from reinsurance in the fourth quarter.

    所以可以說只是保費從一個口袋移到另一個口袋。因此不會影響整個企業的總保費。但第四季淨已賺保費為負 1.9% 與基礎值負 1.2% 之間的差異,真正造成差異的三個組成中,絕大多數來自繳清狀態(paid-up status),其次有一小部分來自遞延利益負債。第四季再保的影響非常小。

  • Alex Scott - Equity Analyst

    Alex Scott - Equity Analyst

  • So is it fair to take that delta between what we saw in 4Q on underlying versus actual and assuming no more reinsurance, that's a fair way to think about the difference that we potentially see in '26? Is that right?

    那麼,是否可以公平地把我們在第四季看到的基礎表現與實際結果之間的差額視為那個 delta,並假設不再有再保險,這樣來理解我們在 2026 年可能看到的差異,是一個合理的思考方式嗎?是這樣嗎?

  • Max Broden - Chief Financial Officer, Senior Executive Vice President

    Max Broden - Chief Financial Officer, Senior Executive Vice President

  • That is a -- I would expect that impact to be slightly smaller, and the reason for that is that we have a declining balance of paid-up impact coming through.

    這個——我預期那個影響會稍微小一些,原因是已繳清(paid-up)影響所帶來的餘額正在下降。

  • Alex Scott - Equity Analyst

    Alex Scott - Equity Analyst

  • Got it. Okay. That's all helpful. And then as a follow-up, I wanted to ask about technology, and obviously, we're getting a lot of questions from clients on artificial intelligence and how it affects different areas of our markets. I'd be interested in your take on what you see, obviously, the opportunities, there's also risks of disintermediation here or there.

    了解。好。這些都很有幫助。接著作為追問,我想問一下科技方面,顯然我們從客戶那裡收到很多關於人工智慧以及它如何影響我們市場不同領域的問題。我很想聽聽你的看法:你看到哪些機會?當然也存在在某些地方被去中介化(disintermediation)的風險。

  • And then maybe separately, if you could just talk about any kind of exposure that you're focused on in the investment portfolio, like software and so forth.

    另外也許分開來談,如果你能談談你在投資組合中關注的任何曝險,例如軟體等等。

  • Daniel Amos - Chairman of the Board, Chief Executive Officer

    Daniel Amos - Chairman of the Board, Chief Executive Officer

  • Why don't I start with the last part there, Alex. Obviously, the software is getting a lot of attention now with all that's going on in the AI world. In our credit portfolio, we have about 1.5% of total exposure to software-related companies. About half of that is in our middle market loan portfolio. Where you'll recall, this is a very well diversified portfolio, all first lien senior secured positions, very small average sizes of about $15 million.

    Alex,我先從你剛才最後那部分開始。顯然,隨著 AI 領域發生的一切,軟體現在受到很多關注。在我們的信用投資組合中,與軟體相關公司的總曝險約占 1.5%。其中大約一半在我們的中型市場(middle market)貸款投資組合裡。你會記得,這是一個高度分散的投資組合,全部都是第一順位留置權(first lien)的高順位擔保部位(senior secured),平均單筆規模很小,約 1,500 萬美元。

  • And then the other half is in our investment grade -- is investment-grade exposure and carries an A minus rating. So there's a lot to like about these software companies from a credit standpoint. We're well aware of the threat from AI, and we're watching it very closely. But right now, we feel very comfortable with our overall exposure to software.

    另外一半在我們的投資級——屬於投資級曝險,且評等為 A-。因此,從信用角度來看,這些軟體公司有很多值得肯定之處。我們非常清楚 AI 帶來的威脅,也正非常密切地觀察。但就目前而言,我們對整體軟體曝險感到非常安心。

  • Virgil Miller - President, President - Aflac U.S.

    Virgil Miller - President, President - Aflac U.S.

  • And this is Virgil. Let me give it to you from an operational standpoint, what we're doing within our businesses. So I spent a lot of time last year in Japan. First, I want to commend our Aflac Japan team. We are making investments in exploring how we can leverage AI in a variety of different ways there, working very strongly with the FSA.

    我是 Virgil。我從營運角度跟你說明我們在各項業務內部正在做的事。所以我去年花了很多時間在日本。首先,我要稱讚我們的 Aflac 日本團隊。我們正在投入資源,探索如何以各種不同方式運用 AI,並且與金融廳(FSA)密切合作。

  • And I would say to you that we're focused a lot on the enrollment process of how we distribute our products. We're also looking at it by way of what AI could do, by way of product innovation and some of the learnings that we've learned through our Japan counterparts, we're leveraging here also in the US.

    我會說,我們很聚焦在投保/加入(enrollment)流程,也就是我們如何分銷我們的產品。我們也在研究 AI 能做些什麼,例如產品創新;而且我們從日本同仁那裡學到的一些經驗,也正在美國這邊加以運用。

  • For the US, what we focused on is, first, looking throughout our company and how AI can assist in making people better at what we do. What we're saying is that technology -- we're not looking to replace the people. It's a high-touch business when it comes to delivering on that promise and paying claims.

    在美國方面,我們首先聚焦的是檢視整個公司,看看 AI 如何協助讓大家把工作做得更好。我們的說法是,科技——我們不是要取代人。在履行承諾與理賠給付方面,這是一門高度重視人際互動(high-touch)的業務。

  • We want to make sure that AI is assisting us with that. So what we've done is where we can automate some of the more routine processes within the claims area, a larger percentage of our claims, especially in all the traditional business, more than 60% is automated, using a lot of the machine learning techniques.

    我們希望確保 AI 能在這方面協助我們。因此,我們所做的是:在理賠領域中,凡是能自動化的一些較例行的流程就加以自動化;我們有更高比例的理賠,特別是在所有傳統業務中,超過 60% 已經自動化,並運用了大量機器學習技術。

  • We apply AI to actually give the claims adjudicator advice on what to look for, but we do not deny or have any claim fully adjudicated by automation without a final person making that decision. We're also looking at, though, how we can help with our enrollment process here in the US.

    我們運用 AI 來實際給理賠審核人員(claims adjudicator)建議,提示應該注意哪些重點;但我們不會在沒有最後由人做出決定的情況下,僅靠自動化就拒賠或讓任何理賠完全由自動化完成審核。此外,我們也在研究如何在美國這裡協助我們的投保/加入(enrollment)流程。

  • So what I mentioned that we're rolling out some enhanced automation in our enrollment that's going to make our agents more efficient as they meet with consumers face-to-face. A lot of how we prepared that technology was done through AI in the background of how we were able to get it to market so fast -- normal -- much faster than normal process before.

    所以我提到,我們正在推出一些在投保/加入流程上的強化自動化,讓我們的業務員在與消費者面對面會談時更有效率。我們在準備這項技術的很多方式上,都在後端運用了 AI,使我們能夠如此快速地把它推向市場——比起以往一般流程——快得多。

  • So I will conclude just by saying, we are certainly looking at how we can leverage AI going forward. It is a part of our DNA. But right now, it's more in an assist role as far as how we're leveraging it as part of our rollout.

    最後我總結一下:我們確實正在思考未來如何運用 AI。它是我們 DNA 的一部分。但就目前而言,在我們推動落地的方式上,它更多是扮演輔助的角色。

  • Operator

    Operator

  • And with that, ladies and gentlemen, we'll be concluding today's question-and-answer session. I'd like to turn the floor back over to David Young for any closing remarks.

    各位女士、先生,今天的問答環節到此結束。我想把時間交回給 David Young,請他做結語。

  • David Young - Vice President - Capital Markets

    David Young - Vice President - Capital Markets

  • Thank you, Jamie, and thank you all for joining us today. I hope you'll mark your calendars also for December 3 to join us for our financial analyst briefing, and we'll be sending out more information in regard to that closer to that date. In the interim, if you have any questions, please reach out to Investor Relations. We'll get back to you or try and help and respond to your questions as soon as we can. Thank you all for joining. Have a good day.

    謝謝你,Jamie,也謝謝各位今天加入我們。也希望各位把 12 月 3 日記在行事曆上,參加我們的金融分析師簡報會;我們會在接近該日期時再提供更多相關資訊。在此期間,如果你有任何問題,請聯繫投資人關係部門。我們會回覆你,或盡快協助並回應你的問題。謝謝各位參與。祝各位有美好的一天。

  • Operator

    Operator

  • And with that, ladies and gentlemen, we'll conclude today's conference call and presentation. We thank you for joining. You may now disconnect your lines.

    那麼,各位女士、先生,今天的電話會議與簡報到此結束。感謝各位加入。你現在可以掛斷電話線路。

  • Editor

    Editor

  • Portions of this transcript that are marked (interpreted) were spoken by an interpreter present on the live call. The interpreter was provided by the company sponsoring this event.

    本逐字稿中標示為(interpreted)的部分,是由現場電話會議中的口譯員所口譯。該口譯員由主辦本活動的公司提供。